3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Lung Neoplasms
3
Multiple Myeloma
2
Carcinoma
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
napabucasin
3
Paclitaxel
3
Irinotecan
3
selpercatinib
2
pralsetinib
2
patritumab
2
Standard of Care
2
Pemetrexed
2
Nivolumab
2
Fluorouracil
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Ascorbic Acid
2
Albumin-Bound Paclitaxel
2
valrubicin
1
sotorasib
1
ribociclib
1
relatlimab
1
pamiparib
1
osimertinib
1
ipatasertib
1
durvalumab
1
dostarlimab
1
cobimetinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Site
×
L-BLP25
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts